Floatz logo

Vistusertib

Recurrent Lung Small Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

291 Active assets in the Recurrent Lung Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Vistusertib is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
56 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →